secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001213900-24-035953
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra R&D Day: reproxalap NDA resubmission H2 2024; positive preclinical data for ADX-246, ADX-629
--------------------------------------------------------------------------------

- Reproxalap NDA resubmission expected H2 2024, pending Phase 3 dry eye chamber trial results and FDA discussions.
- ADX-629 showed statistically significant improvement in EASI, itching, and POEM scores in Phase 2 atopic dermatitis trial.
- ADX-246 reduced hepatic acetaldehyde, histopathology, and liver enzymes in preclinical alcoholic hepatitis model.
- ADX-629 enhanced GLP-1-mediated weight and fat mass loss in a diet-induced obesity mouse model.
- Next-generation RASP modulators ADX-248 and ADX-246 demonstrated broad activity in preclinical inflammation models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024035953/0001213900-24-035953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024035953/ea0204620-8k_aldey.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-035953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer